Introduction Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the
treatment of Crohn's disease (CD) and ulcerative colitis (UC) after the phase III trial …

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis
and Crohn's disease. Although having a common global pathophysiological mechanism …

Background Real‐world data on clinical outcomes of ustekinumab in ulcerative colitis are
lacking. Objective To assess short‐and long‐term clinical outcomes of ustekinumab in …

Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in
ulcerative colitis (UC), but few real‐life long‐term data are currently available. Aims To …

Abstract Background and Aims The development programm UNIFI has shown promising
results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in …

Background Evidence on real‐world outcomes of ustekinumab for ulcerative colitis (UC)
patients is needed. Aims To summarise evidence on the real‐world outcomes of …

Background Efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC)
has been demonstrated in clinical trials, but few real-world data are available so far. The aim …

Study Design This retrospective cohort study included adults with UC (ICD-10-CM 51x)
initiating ustekinumab at Brigham and Women's Hospital, Massachusetts General Hospital …

Background Active and severe ulcerative colitis (UC) and non-response to 5-aminosalicylic
acid (5-ASA) are related to poor outcomes and should be accurately identified. Several …

Objective This study aimed to evaluate ustekinumab efficacy, effectiveness, and safety as a
treatment for ulcerative colitis in adult patients. Methods A systematic review of the efficacy …